News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

What Sarepta Therapeutics (SRPT)’ Next Move Should Be


4/22/2014 8:16:45 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

In a second dramatic reversal for a promising treatment for a terrible disease, Sarepta Therapeutics SRPT +2.24% announced that it will file an application with the Food and Drug Administration for its drug eteplirsen, to treat Duchenne muscular dystrophy that is caused by a specific mutation, by the end of 2014. The news should please both investors and patient advocates who have campaigned for the drug’s approval.

Hey, check out all the research scientist jobs. Post your resume today!

Read at Forbes

comments powered by Disqus
Forbes
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES